Thrombomodulin, plasminogen activator inhibitor type 1 (PAI-1) and fibronectin as biomarkers of endothelial damage in preeclampsia and eclampsia

被引:49
|
作者
Shaarawy, M
ElDidy, H
机构
[1] Dept. of Obstetrics and Gynecology, Faculty of Medicine, Cairo University, Cairo
关键词
fibronectin; plasminogen activator inhibitor type 1; thrombomodulin; preeclampsia; eclampsia;
D O I
10.1016/S0020-7292(96)02755-5
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: Preeclampsia has been recently suggested to be an endothelial cell disorder. This study was initiated to determine the levels of various biomarkers of endothelial damage in preeclampsia and eclampsia. Methods: Blood samples were withdrawn from 70 pregnant women in their third trimester grouped as 25 mild preeclampsia, 15 severe preeclampsia, 10 eclampsia and 20 normotensive healthy women (controls) for the determination of thrombomodulin by ELISA, PAI-1 by urokinase method and fibronectin by radial immunodiffusion. Results were statistically analyzed by Student's t-test. Results: Circulation levels of PAI-1, thrombomodulin and fibronectin were increased with increasing severity of the disease. Thrombomodulin was the only parameter which did not change significantly in mild preeclampsia. The average percent increments in preeclampsia and eclampsia were 63%, 102% and 132%, respectively. Conclusions: These results demonstrate that fibronectin may be a more valuable biomarker than thrombomodulin and PAI-I for the assessment of endothelial damage in preeclampsia and eclampsia.
引用
收藏
页码:135 / 139
页数:5
相关论文
共 50 条
  • [41] Plasminogen activator inhibitor 1 (PAI-1):: in vitro activities and clinical relevance
    Horrevoets, AJG
    BRITISH JOURNAL OF HAEMATOLOGY, 2004, 125 (01) : 12 - 23
  • [42] Modulation of plasminogen activator inhibitor-1 (PAI-1) by the naphthoquinone shikonin
    Han, Tingting
    Zhang, Guangping
    Yan, Dong
    Yang, Hong
    Ma, Tonghui
    Ye, Zuguang
    FITOTERAPIA, 2016, 113 : 117 - 122
  • [43] ROLE OF PLASMINOGEN-ACTIVATOR INHIBITOR-1 (PAI-1) IN DIC
    MATSUDA, T
    ASAKURA, H
    SAITO, M
    JOKAJI, H
    UOTANI, C
    KUMABASHIRI, I
    MORISHITA, E
    YAMAZAKI, M
    THROMBOSIS RESEARCH, 1991, 63 (02) : 269 - 269
  • [44] Past, Present, and Future Perspectives of Plasminogen Activator Inhibitor 1 (PAI-1)
    Morrow, Gael B.
    Mutch, Nicola J.
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2023, 49 (03): : 305 - 313
  • [45] Genetics of Plasminogen Activator Inhibitor-1 (PAI-1) in a Ghanaian Population
    White, Marquitta J.
    Kodaman, Nuri M.
    Harder, Reed H.
    Asselbergs, Folkert W.
    Vaughan, Douglas E.
    Brown, Nancy J.
    Moore, Jason H.
    Williams, Scott M.
    PLOS ONE, 2015, 10 (08):
  • [46] The international standard for plasminogen activator inhibitor-1 (PAI-1) activity
    Gaffney, PJ
    Edgell, TA
    THROMBOSIS AND HAEMOSTASIS, 1996, 76 (01) : 80 - 83
  • [47] STABILIZATION OF PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1 (PAI-1) ACTIVITY BY ARGININE - POSSIBLE IMPLICATIONS FOR THE INTERACTION OF PAI-1 WITH VITRONECTIN
    KEIJER, J
    LINDERS, M
    EHRLICH, H
    GEBBINK, RK
    PANNEKOEK, H
    FIBRINOLYSIS, 1990, 4 (03) : 153 - 159
  • [48] DAYTIME FLUCTUATIONS OF PLASMINOGEN-ACTIVATOR INHIBITOR-1 (PAI-1) IN POPULATIONS WITH HIGH PAI-1 LEVELS
    JUHANVAGUE, I
    ALESSI, MC
    RACCAH, D
    AILLAUD, MF
    BILLEREY, M
    ANSALDI, J
    PHILIPJOET, C
    VAGUE, P
    THROMBOSIS AND HAEMOSTASIS, 1992, 67 (01) : 76 - 82
  • [49] Mechanistic studies on the inactivation of plasminogen activator inhibitor 1 (PAI-1) by the small molecule PAI-1 antagonist PAI-749
    Gardell, SJ
    Antrilli, TM
    Elokdah, H
    Krueger, JA
    Mayer, S
    Orcutt, SJ
    Vlasuk, GP
    Crandall, DL
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2006, 26 (05) : E104 - E104
  • [50] PLASMINOGEN-ACTIVATOR INHIBITOR-1(PAI-1) AND TISSUE-PLASMINOGEN ACTIVATOR PLASMINOGEN-ACTIVATOR INHIBITOR-1(TPA-PAI-1) IN IDDM - PROFILE BY COMPLICATIONS
    SUMINSKI, R
    DASILVA, S
    SMITH, M
    ERBEY, J
    DIABETES, 1994, 43 : A197 - A197